ArticleInvestigational new drugs2015

Phase 1 combination study of eribulin mesylate with trastuzumab for advanced or recurrent human epidermal growth factor receptor 2 positive breast cancer.

Hirofumi Mukai et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.